Literatur
-
1
Tukiainen P, Taskinen E, Holsti P, Korhola O, Valle M.
Prognosis of cryptogenic fibrosing alveolitis.
Thorax.
1983;
38
349-355
-
2
Coultas D B, Zumwalt R E, Black W C, Sobonya R E.
The epidemiology of interstitial lung diseases.
Am J Respir Crit Care Med.
1994;
150
967-972
-
3
Turner-Warwick M, Burrows B E, Johnson A.
Cryptogenic fibrosing alveolitis: clinical features and their influence on survival.
Thorax.
1980;
35
593-599
-
4
Majumdar S, Li D, Ansari T, Pantelidis P, Black C M, Gizycki M, du Bois R M, Jeffery P K.
Tissue cytokine profiles of cryptogenic fibrosing alveolitis (CFA) and fibrosing alveolitis associated with systemic sclerosis (FASSc) are distinct: a quantitative in situ study of open lung biopsies.
Eur Respir J.
1999;
14
251-257
-
5
Elias A D.
Salvage therapy for soft tissue sarcomas.
Semin Oncol.
1994;
21
S7: 76-81
-
6
Barth A, Morton D L.
The role of adjuvant therapy in melanoma management.
Cancer.
1995;
75
726-734
-
7
Windbichler G H, Hausmaninger H, Stummvoll W, Graf A H, Kainz C, Lahodny J, Denison U, Muller Holzner E, Marth C.
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.
Br J Cancer.
2000;
82
1138-1144
-
8
Gurujeyalakshmi G, Giri S N.
Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: Downregulation of TGF-β and procollagen I and III gene expression.
Exp Lung Res.
1995;
21
791-808
-
9
Ziesche R, Kink E, Herold C, Podolsky A, Block L H.
Therapy of chronic interstitial lung disease with a combination of Interferon gamma and low-dose prednisolone.
Chest.
1996;
110
25S
-
10
Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L H.
A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.
N Engl J Med.
1999;
314
1264-1269
1 Herrn Prof. Dr. med. Heinrich Matthys zum 65. Geburtstag gewidmet.
Dr R Ziesche
Abteilung Innere Medizin IV Universität Wien
Währinger Gürtel 18 - 20 1090 Wien Österreich
